Intelligent Bio Solutions Posts 46% Revenue Growth, Cartridge Sales Surge 59%
Event summary
- Q3 revenue hit $1.06M, up 46% YoY, with cartridge sales accounting for 66% of revenue.
- Nine-month revenue reached $3.07M, up 39% YoY, with gross margin expanding to 50.5% in Q3.
- Cartridge sales surged 59% YoY, reflecting strong recurring revenue from installed base.
- Other sales grew 80% YoY, signaling broadening product ecosystem.
- Cash reserves increased to $6.86M as of March 31, 2026.
The big picture
Intelligent Bio Solutions is capitalizing on its razor-razorblade model, with recurring cartridge sales driving 66% of Q3 revenue. The company's ability to expand gross margins while reducing marketing spend suggests operational efficiencies are kicking in. Success hinges on navigating FDA approvals to tap into the multi-billion-dollar U.S. drug screening market.
What we're watching
- Regulatory Milestones
- The pace at which FDA 510(k) clearance progresses will determine U.S. market entry timing.
- Margin Expansion
- Whether the 50% gross margin threshold can be sustained as cartridge sales scale.
- Customer Diversification
- How Bouygues UK and other safety-critical sector deals will impact revenue diversification.
Related topics